Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Acies Bio D O O is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, which means that every pending case is being handled by a different individual. This variety requires the company to adapt its prosecution tactics to 4 different examiner styles simultaneously. The portfolio is spread across 3 distinct art units, indicating a range of biological or pharmaceutical classifications for these 4 pending office actions.
ROBINSON, HOPE A is the busiest examiner identified, though she is only responsible for 1 pending office action. Because each of the 4 distinct examiners manages exactly 1 pending office action, no single examiner has a disproportionate influence over the portfolio's overall trajectory. Practitioners should prepare for 4 unique sets of examiner feedback across the 3 distinct art units involved in these proceedings. The distribution of 4 pending office actions across 4 distinct examiners ensures that the company's applications are not dependent on the views of a single individual.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, HOPE A | 1 | 67.7% | +43.1% |
| MAHADEVAN, JANAKI ANANTH | 1 | — | — |
| CREWS, JARET JAMES | 1 | 44.7% | +70.3% |
| PAK, YONG D | 1 | 74.6% | +14.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18881959 | PEROXIDASE BASED BIOCONTROL AGENTS | ROBINSON, HOPE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037918 | GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS | PAK, YONG D | 28d |
| 18881959 | PEROXIDASE BASED BIOCONTROL AGENTS | ROBINSON, HOPE A | — |
| 18556489 | NOVEL SPINOSYN PRODRUGS | CREWS, JARET JAMES | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1691 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18881959 | PEROXIDASE BASED BIOCONTROL AGENTS | ROBINSON, HOPE A | — | §102§112 | Non-Final OA | — | Pending | Jan 07, 2025 |
| 18563056 | NOVEL SPINOSYN COMPOUNDS | MAHADEVAN, JANAKI ANANTH | 1693 | §103DP | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18556489 | NOVEL SPINOSYN PRODRUGS | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | — | Pending | Oct 20, 2023 |
| 18037918 | GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS | PAK, YONG D | 1652 | §103 | Final Rejection | 28d | Pending | May 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial